MCADD is typically diagnosed through newborn screening, which measures the levels of specific metabolites in the blood. Elevated levels of octanoylcarnitine and other medium-chain acylcarnitines are indicative of MCADD. Genetic testing can confirm the diagnosis by identifying mutations in the ACADM gene.
